BRPI0416920A - redução de cicatriz dérmica - Google Patents

redução de cicatriz dérmica

Info

Publication number
BRPI0416920A
BRPI0416920A BRPI0416920-4A BRPI0416920A BRPI0416920A BR PI0416920 A BRPI0416920 A BR PI0416920A BR PI0416920 A BRPI0416920 A BR PI0416920A BR PI0416920 A BRPI0416920 A BR PI0416920A
Authority
BR
Brazil
Prior art keywords
dermal scar
scar reduction
dermal
reduction
waf1
Prior art date
Application number
BRPI0416920-4A
Other languages
English (en)
Inventor
Danling Gu
Monica Zepeda
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of BRPI0416920A publication Critical patent/BRPI0416920A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"REDUçãO DE CICATRIZ DéRMICA". A presente invenção refere-se a um método e composições para redução ou inibição de cicatriz dérmica através de expressão de p21¬ WAF1/Cip1¬ em um local de ferimento são providos.
BRPI0416920-4A 2003-11-24 2004-11-23 redução de cicatriz dérmica BRPI0416920A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52499303P 2003-11-24 2003-11-24
PCT/US2004/039633 WO2005051971A1 (en) 2003-11-24 2004-11-23 Reduction of dermal scarring

Publications (1)

Publication Number Publication Date
BRPI0416920A true BRPI0416920A (pt) 2007-01-23

Family

ID=34632948

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416920-4A BRPI0416920A (pt) 2003-11-24 2004-11-23 redução de cicatriz dérmica

Country Status (13)

Country Link
US (3) US7465442B2 (pt)
EP (1) EP1692154A4 (pt)
JP (2) JP4842139B2 (pt)
KR (1) KR101167330B1 (pt)
CN (2) CN101507822B (pt)
AU (1) AU2004293474B2 (pt)
BR (1) BRPI0416920A (pt)
CA (1) CA2546287C (pt)
IL (1) IL175603A (pt)
NO (1) NO20062978L (pt)
NZ (1) NZ546983A (pt)
WO (1) WO2005051971A1 (pt)
ZA (1) ZA200604147B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546983A (en) * 2003-11-24 2009-05-31 Canji Inc Reduction of dermal scarring
CN103271761B (zh) 2008-01-14 2015-10-28 康文图斯整形外科公司 用于骨折修补的装置和方法
EP2340309A2 (en) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters
WO2011088172A1 (en) 2010-01-15 2011-07-21 Brenzel Michael P Rotary-rigid orthopaedic rod
EP2523616B1 (en) 2010-01-20 2019-04-17 Conventus Orthopaedics, Inc. Apparatus for bone access and cavity preparation
JP2013521880A (ja) 2010-03-08 2013-06-13 コンベンタス オーソピディックス， インコーポレイテッド 骨インプラントを固定するための装置および方法
BR112012024049A2 (pt) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
CA2932753A1 (en) * 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
JP6539652B2 (ja) 2013-12-12 2019-07-03 コンベンタス オーソピディックス， インコーポレイテッド 組織変位ツールおよび方法
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
CN109069559A (zh) 2016-04-14 2018-12-21 崔泽尔有限公司 病毒载体稳定化
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
WO2019010252A2 (en) 2017-07-04 2019-01-10 Conventus Orthopaedics, Inc. Apparatus and methods for treatment of a bone

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4505266A (en) 1981-10-26 1985-03-19 Massachusetts Institute Of Technology Method of using a fibrous lattice
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
AU8532691A (en) * 1990-08-01 1992-03-02 Chiron Ophthalmics Inc. Method for treating corneal endothelial wounds
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5596079A (en) * 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
EP0665886B1 (en) 1992-10-16 2003-06-11 Cold Spring Harbor Laboratory Cyclin complex rearrangement and uses related thereto
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
FR2702152B1 (fr) 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
EP0723402B1 (en) 1993-08-30 2010-08-18 Baylor College Of Medicine Senescent cell-derived inhibitors of dna synthesis
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
NZ284612A (en) * 1994-03-18 1997-09-22 Univ Utah Res Found Multiple tumour suppressor (mts) gene and its use in the diagnosis and treatment of cancer
ATE283355T1 (de) 1994-05-24 2004-12-15 Baylor College Medicine Mimetika von aus alternden zellen abgeleitete hemmer der dna synthese
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5631156A (en) * 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
WO1996012506A1 (en) 1994-10-24 1996-05-02 Baylor College Of Medecine Senescent cell-derived inhibitors of dna synthesis
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
WO1996019244A1 (en) 1994-12-22 1996-06-27 The University Of North Carolina At Chapel Hill DNA ENCODING A 20 Kd CDK6 INHIBITING PROTEIN
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5856094A (en) 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US6027742A (en) * 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
SK6598A3 (en) 1995-07-17 1998-09-09 Univ Texas P16 expression constructs and their application in cancer therapy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
AU1837197A (en) * 1996-01-26 1997-08-20 United States of America, represented by the Secretary, Department of Health and Human Services, The National Institutes of Health, The Hydroxylamine compositions for the prevention or retardation of cataracts
WO1997037542A1 (en) 1996-04-10 1997-10-16 University Of Southern California Gene therapy for proliferative vitreoretinopathy
IT1285790B1 (it) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
US6274614B1 (en) * 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
JPH11205102A (ja) * 1998-01-13 1999-07-30 Mitsubishi Electric Corp 遅延同期回路
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
WO2001013960A1 (en) * 1999-08-20 2001-03-01 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for in vivo gene delivery to sites of cartilage damage
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
NZ546983A (en) * 2003-11-24 2009-05-31 Canji Inc Reduction of dermal scarring
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders

Also Published As

Publication number Publication date
CN1906205A (zh) 2007-01-31
JP2011207912A (ja) 2011-10-20
CN101507822A (zh) 2009-08-19
IL175603A (en) 2011-02-28
KR101167330B1 (ko) 2012-07-23
US20050271623A1 (en) 2005-12-08
JP2007512377A (ja) 2007-05-17
US20110129534A1 (en) 2011-06-02
US7465442B2 (en) 2008-12-16
EP1692154A4 (en) 2009-07-08
AU2004293474B2 (en) 2010-12-23
US8329671B2 (en) 2012-12-11
JP4842139B2 (ja) 2011-12-21
KR20060127414A (ko) 2006-12-12
AU2004293474A1 (en) 2005-06-09
CA2546287A1 (en) 2005-06-09
NZ546983A (en) 2009-05-31
CN100482674C (zh) 2009-04-29
CA2546287C (en) 2014-04-22
US20090142397A1 (en) 2009-06-04
ZA200604147B (en) 2007-11-28
IL175603A0 (en) 2006-09-05
CN101507822B (zh) 2012-06-06
NO20062978L (no) 2006-06-26
EP1692154A1 (en) 2006-08-23
WO2005051971A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
WO2009026166A3 (en) Antiinfective flavonol compounds and methods of use thereof
BR0312957A (pt) Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
MXPA04001323A (es) Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso.
AU2003257937A1 (en) Methods and compositions for treatment of dermal conditions
BRPI0312331A2 (pt) composições de ácido hialurônico e métodos de emprego.
DK1660528T3 (da) Mutein af tåre-lipocalin
ATE476427T1 (de) Difluormethyl thiazolyl carboxanilide
SE0301886D0 (sv) New use V
SE0301888D0 (sv) New use VII
WO2008151460A3 (en) Cooling compounds
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
ATE530509T1 (de) Neue pilzliche inokulumzusammensetzungen, verfahren zu ihrer herstellung und ihre verwendung für die verbesserung des wachstums von kulturen
ITMI20020281A1 (it) Composti fosfazenici ciclici e loro uso come addittivi di oli perfluoropolieterei
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
ATE535510T1 (de) Benzylamine, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmende mittel
TW200602031A (en) Antiinflammatory and pain-relieving agent for external, use
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
DE60029954D1 (de) Dermale anästhetika
NO20062978L (no) Reduksjon av dermal arrdannelse
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
SE0301883D0 (sv) New use II
WO2008126652A1 (ja) 皮膚外用組成物
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
SE0301884D0 (sv) New use III

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07H 21/04 , C12N 15/00 , C12N 15/09 , C12N 15/63 , C12N 15/85 , A61K 48/00

Ipc: A61K 48/00 (2006.01), C12N 15/00 (2006.01), C12N 1

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]